CAH

Cardinal Health raises its fiscal 2027 earnings outlook as specialty growth, strong generics demand and customer renewals offset medical distribution pressures.

Cardinal Health beats Q1 FY27 earnings and revenue estimates, fueled by pharmaceutical sales growth, and raises its full-year earnings outlook.

While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cardinal Health (CAH) came out with quarterly earnings of $3.26 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.55 per share a year ago.

First quarter revenue increased 5% to $67.5 billion GAAP 1 operating earnings increased 13% to $753 million; GAAP diluted EPS increased 27% to $2.38 Non-GAAP operating earnings increased 17% to $1.0 billion; non-GAAP diluted EPS increased 28% to $3.26 Cardinal Health raises fiscal year 2027 non-GAAP EPS guidance2 to $12.80 to $13.00, 17% to 19% growth3 from its FY26 ex-tariff refund baseline and 14% to 15% growth from reported FY26 results Cardinal Health completes $500 million share repurchase program in first quarter DUBLIN, Ohio, Nov. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2027 revenues of $67.5 billion, an increase of 5% from the first quarter of fiscal year 2026. First quarter GAAP operating earnings increased 13% to $753 million and GAAP diluted earnings per share (EPS) increased 27% to $2.38.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.

Cardinal Health CAH is scheduled to report first-quarter fiscal 2027 results on Nov. 5, before the market opens. The company entered the quarter with strong pharmaceutical demand, expanding specialty operations and ongoing improvement initiatives in its medical distribution business.

I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.

Cardinal Health (CAH) closed at $253.71 in the latest trading session, marking a +2.41% move from the prior day.

As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.